Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Share-based Compensation (2016 - 2025)

Sangamo Therapeutics has reported Share-based Compensation over the past 16 years, most recently at $2.1 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $2.1 million for Q4 2025, down 35.12% from a year ago — trailing twelve months through Dec 2025 was $9.1 million (down 26.68% YoY), and the annual figure for FY2025 was $9.1 million, down 26.68%.
  • Share-based Compensation for Q4 2025 was $2.1 million at Sangamo Therapeutics, roughly flat from $2.1 million in the prior quarter.
  • Over the last five years, Share-based Compensation for SGMO hit a ceiling of $9.5 million in Q2 2021 and a floor of $2.1 million in Q3 2025.
  • Median Share-based Compensation over the past 5 years was $6.5 million (2023), compared with a mean of $5.7 million.
  • Biggest five-year swings in Share-based Compensation: skyrocketed 40.2% in 2021 and later tumbled 67.15% in 2024.
  • Sangamo Therapeutics' Share-based Compensation stood at $8.1 million in 2021, then rose by 2.13% to $8.2 million in 2022, then dropped by 25.96% to $6.1 million in 2023, then crashed by 46.24% to $3.3 million in 2024, then tumbled by 35.12% to $2.1 million in 2025.
  • The last three reported values for Share-based Compensation were $2.1 million (Q4 2025), $2.1 million (Q3 2025), and $2.2 million (Q2 2025) per Business Quant data.